Vericel Corp
Ann Arbor
About Vericel Corp
Vericel (formerly Aastrom Biosciences) is developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. Aastrom markets two autologous cell therapy products in the United States for the treatment of cartilage repair and skin replacement. Aastrom is also developing MACI™, a third-generation autologous chondrocyte implantation product for the treatment of focal chondral cartilage defects in the knee, and ixmyelocel-T, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 251 – 500
- Estimated revenue: $100K – $500K
- Total funding: $157.3M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jun 2018)
- Ticker: nasdaq:VCEL
- Website: vcel.com
- Phone: (617)588-5555
Industries & Categories
Biotechnology, Life Science, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/vericel-corp-6167 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.